ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1341	National Cancer Institute	Html	en	Smokeless Tobacco and Cancer	A fact sheet about the health risks associated with the use of smokeless tobacco.	tobacco cut size 0.465919 NCI smoking cessation 0.353151 safe level 0.345736 oral tobacco 0.470575 nicotine addiction 0.363201 Human Services 0.340767 Health State-of-the-Science conference 0.343313 U.S. Department 0.340786 tobacco-specific nitrosamines 0.373338 tobacco fertilizer 0.451995 advisory committee 0.346137 powdered tobacco 0.462627 Health Organization International 0.342988 oral cancer 0.332186 National Institutes 0.343448 Watson C. Surveillance 0.3381 Tobacco Control Monograph 0.451686 moist snuff 0.436686 precancerous white patches 0.344838 International Agency 0.339252 NCI’s Smoking 0.334129 Tobacco Research 0.437462 NCI fact sheet 0.385333 lower lip 0.34967 esophageal cancer 0.332063	nicotine stays 0.353085 Yes. All tobacco 0.450832 National Cancer Institute 0.373261 LiveHelp online chat 0.341688 American snuff 0.346643 polynuclear aromatic hydrocarbons 0.347124 Eastern time 0.340428 spitting tobacco 0.470917 online text chat 0.340605 polycyclic aromatic hydrocarbons 0.346589 smokeless tobacco products 0.615213 smokeless tobacco cause 0.576883 Nicotine content 0.350271 un-ionized nicotine 0.348074 Surgeon General 0.344959 smokeless tobacco 0.995709 Yes. Smokeless tobacco 0.55885 dry snuff 0.363969 noncancerous oral conditions 0.343638 NIH State-of-the-Science Panel 0.338818 tobacco cause cancer 0.483342 smoking cessation counselor 0.38611 tobacco juices 0.469352 harmful chemicals 0.350583	CLICK HERE
1537	National Cancer Institute	Html	en	Newcastle Disease Virus (PDQ®)–Health Professional Version	Expert-reviewed information summary about the use of Newcastle disease virus (NDV) as a treatment for people with cancer.	metastatic tumor cells 0.405592 tumor cell lines 0.391976 human cancer cells 0.50054 genetically engineered NDV 0.389911 NDV oncolysates 0.413317 autologous tumor vaccine 0.41773 infected cells 0.416882 historical control subjects 0.398257 irradiated ESb cells 0.39152 Cancer Res 0.395898 disease virus therapy 0.398313 virus-modified tumor cells 0.412589 virus-modified autologous tumor 0.394368 autologous tumor cell 0.439505 patients 0.465722 Natl Cancer Inst 0.401926 human tumor cells 0.440276 lytic strains 0.409693 normal human cells 0.424643 cell vaccines 0.393769 et al. 0.391296 autologous tumor cells 0.542424 colorectal cancer patients 0.390231 cancer cells 0.51627 newcastle disease virus 0.925041	primary tumor cells 0.39623 PUBMED Abstract 0.426283 disease virus vaccine 0.404352 uninfected cancer cells 0.394475 tumor cells 0.60365 tumor cell vaccine 0.404276 progeny virus particles 0.393227 NDV 0.533791 Abstract 0.460011 human immune cells 0.389104 autologous cells 0.393227 NDV genetic material 0.390979 nonlytic NDV strains 0.407173 NDV-infected cancer cells 0.395154 malignant melanoma patients 0.394264 Human tumor cell 0.388361 renal cell carcinoma 0.423539 cells 0.622446 main NDV proteins 0.390649 ESb cells 0.400925 NDV strains 0.410203 regional lymph nodes 0.425639 cancer 0.567906 irradiated tumor cells 0.398885	CLICK HERE
1603	National Cancer Institute	Html	en	Essiac/Flor Essence (PDQ®)–Health Professional Version	Expert-reviewed information summary about the use of Essiac/Flor Essence as a treatment for people with cancer. Note: The information in this summary is no longer being updated and is provided for reference purposes only.	cancer treatment 0.476893 breast cancer patient 0.447748 peer-reviewed scientific literature 0.505169 Flor Essence 0.910617 Canada’s Emergency 0.483591 Essiac 0.743648 Emergency Drug Release 0.58138 market Essiac 0.538568 Essiac herbal tonics. 0.550519 Flor Essence tea 0.527471 health conditions 0.443693 Drug Release Program 0.5531 cancer information summary 0.4699 IND application 0.450106 clinical drug research 0.445755 Rheum palmatum L. 0.477337 cancer patients 0.491951 Investigational New Drug 0.44454 National Health 0.471032 New Drug Application 0.442963 Canadian Department 0.469814 four-herb recipe 0.472871 preclinical new drug 0.49467 cancer cell line. 0.452401	Health Protection Branch 0.470254 Essiac herbs 0.554006 United States 0.45534 Human/Clinical Studies section 0.535541 specific disease treatment 0.444683 Indian rhubarb root 0.47211 Flor Essence formulas 0.534076 Trifolium pratense L. 0.442662 health tonics 0.472986 Rumex acetosella L. 0.474473 conventional anticancer treatments 0.463312 human breast cancer 0.444889 Cnicus benedictus L. 0.443598 Essence herbal teas. 0.46868 dietary supplements 0.454376 Royal Cancer Commission 0.448762 Essiac’s safety 0.539442 new drug submission 0.492934 cancer patients. 0.445606 breast cancer 0.462902 Human Prescription Drugs 0.462631 Ulmus fulva Michx. 0.475105 cancer 0.532647 Laboratory/Animal/Preclinical Studies section 0.471204	CLICK HERE
1696	National Cancer Institute	Html	en	Topics in Integrative, Alternative, and Complementary Therapies (PDQ®)–Health Professional Version	Expert-reviewed information summary that contains information on integrative, complementary, and/or alternative therapies for people with cancer.	cancer treatment 0.500109 standard treatments 0.546145 National Health Interview 0.49394 randomized controlled trials 0.478599 good manufacturing processes 0.485786 Cancer Complementary 0.466196 blood cell count 0.487384 NCI Fact Sheets 0.492301 concomitantly administered drugs 0.486833 depression management 0.497623 cancer information summary 0.503433 potentially active ingredients 0.480985 PDQ summaries 0.45939 St. John 0.975444 cancer patients 0.494368 NCI Fact 0.496884 wort 0.678406 effects 0.47211 complementary therapies 0.460635 cancer survivors 0.459401 PDQ summary section 0.501629 human immunodeficiency virus 0.480593 various metabolic enzymes 0.481932 major active constituents 0.486518 commonly treated symptoms 0.485606	Chinese medical therapies 0.495937 antidepressant therapy 0.478022 deep breathing exercises. 0.492057 Complementary medicine 0.467053 CAM therapies 0.48574 specific PDQ summary 0.501712 dietary supplements 0.496339 systemic concentrations 0.461386 alternative medicine 0.659692 herbal agent 0.488319 natural killer cell 0.486571 lower concentrations 0.45956 traditional Chinese medicine 0.494167 clinically important effect 0.485748 monoamine oxidase inhibitor 0.490216 PDQ summary 0.540549 randomized controlled trials. 0.478417 popular herbal agent 0.484348 NCI Fact Sheet 0.49194 major depressive disorder 0.543366 Alternative Medicine website 0.499408 sufficient concentrations 0.46476 milder depression 0.458918 cancer 0.510149	CLICK HERE
1725	National Cancer Institute	Html	en	Inflammatory Breast Cancer	A fact sheet about the diagnosis and treatment of inflammatory breast cancer (IBC), an uncommon type of cancer in which the breast becomes red, swollen, and warm.	breast cancer talk 0.38738 ongoing clinical trials 0.322108 breast cancer biology 0.384329 Cancer Treatment Research 0.336489 MS. Inflammatory breast 0.412908 clinical trials 0.369256 Post-mastectomy radiation therapy 0.322454 breast size 0.368687 peau d'orange 0.322535 primary inflammatory breast 0.413233 adjuvant therapy 0.323679 inflammatory breast cancers 0.456146 neoadjuvant chemotherapy 0.327114 entire affected breast 0.371358 cancer recurrence 0.326653 radiation therapy 0.339981 Adjuvant systemic therapy 0.323571 Cancer Survival 0.32586 Cancer Journal 0.32501 invasive breast cancers 0.36818 women 0.331101 sponsors clinical trials 0.32312 Breast reconstruction 0.363182 multimodal approach 0.325682 cancer cells 0.367244	Breast Diseases 0.36337 M. Inflammatory breast 0.415692 HER2-positive breast cancer 0.393048 National Cancer Database 0.332281 nci-supported clinical trials 0.33341 National Cancer Institute 0.374989 hormone therapy 0.325328 estrogen-dependent cancer cells 0.336098 breast carcinoma incidence 0.386211 African American women 0.324285 Inflammatory breast tumors 0.439717 lymph vessels 0.32463 cancer detection 0.328538 neoadjuvant HER2-directed therapy 0.322104 inflammatory breast carcinoma 0.435431 dense breast tissue 0.375347 abnormal breast warmth 0.375148 inflammatory breast cancer 0.961199 Swollen lymph nodes 0.324354 cancer clinical trials 0.346503 Clinical Cancer Research 0.336483 postoperative radiation therapy 0.322326 et al 0.375354 cancer patient 0.327473	CLICK HERE
2021	National Cancer Institute	Html	es	Prevención del cáncer de cuello uterino (PDQ®)–Versión para pacientes	Información revisada por expertos sobre los factores que pueden aumentar el riesgo de cáncer de cuello uterino y los enfoques que podrían ayudar a la prevención de esta enfermedad.	Visuals Online 0.544747 PDQ Exámenes 0.729141 Internet NCI 0.599334 siguientes factores 0.942852 voluntarios sanos 0.571782 Physician Data Query 0.821847 Estados Unidos 0.732136 suficiente ejercicio 0.608117	prevención revisa 0.577919 PDQ Prevención 0.648162 cuánto tiempo 0.58363 National Cancer Institute 0.579131 invasivo aumenta 0.607513 siguientes riesgos 0.566231 siguientes sumarios 0.745167 Instituto Nacional 0.648132	CLICK HERE
2050	National Cancer Institute	Html	es	Análisis del antígeno prostático específico (PSA)	Hoja informativa sobre la prueba del antígeno prostático específico (PSA) y los exámenes selectivos de detección para el cáncer de próstata, y clarifica los beneficios y limitaciones de dicha prueba.	posibles complicaciones 0.529476 United States Preventive 0.549836 hiperplasia prostática benigna 0.569875 fusión génica tmprss2-erg 0.5485 estudio plco 0.535774 PLCO trials 0.538088 eréctil o incontinencia 0.532144 médico quizás 0.54755 ng per milliliter 0.54786 concentration-based assay 0.526257 Pauler DK 0.526835 structure-based isopsa assay 0.54715 estudio clínico plco 0.561758 tanta lentitud 0.531594 posibles perjuicios 0.59922 riesgos y beneficios 0.531533 Servicios Preventivos 0.526931 European Randomised Study 0.54659 hiperplasia benigna 0.602949 Preventive Health Services 0.541802 llamadas isoformas 0.529743 Screening Draft Recommendations 0.555159	Hugosson J 0.571924 espectro de  isoformas 0.553214 Instituto Nacional 0.525806 próstata en asociación 0.528933 PSA quizás 0.924082 posibles efectos 0.527227 Internal Medicine 0.527548 Services Task Force 0.63375 among men with 0.545229 estados benignos 0.530298 agrandamiento benigno 0.537792 PubMed Abstract 0.784346 prostate cancer 0.975142 estadio inicial quizás 0.562336 obstante exámenes 0.563732 New England Journal 0.630867 Goodman PJ 0.525307 de 1 muerte 0.528041 Roobol MJ 0.576631 pequeños tumores 0.530536 Heijnsdijk EAM 0.527351 Hafron JM 0.526062	CLICK HERE
2067	National Cancer Institute	Html	es	Terapia hormonal para el cáncer de seno	Hoja informativa que describe la terapia hormonal y su función en la prevención y tratamiento del cáncer de seno. Incluye información acerca de los efectos secundarios posibles y de los fármacos que pueden interferir con la terapia hormonal.	Surgical Adjuvant Breast 0.34336 Lancet Oncology 0.360626 Sestak I 0.320955 seno her2 y HR 0.354769 endocrine-responsive early breast 0.32332 endocrine therapy 0.324855 Preventing breast 0.319374 advanced breast 0.370204 Adjuvant hormonal therapy 0.333366 Cuzick J 0.320795 Vogel VG 0.310952 as adjuvant treatment 0.327521 efectos agonistas 0.311137 combined survival analysis 0.309596 Pippen J 0.31114 randomized trial comparing 0.312309 Collaborative Group 0.311107 seno hr 0.420398 hormonal therapy 0.348519 PubMed Abstract 0.906244 Surgical Oncology Clinics 0.312057 Clinical Oncology 0.330375 with advanced breast 0.322297 prior endocrine therapy 0.310537 early breast cancer 0.522236	alto riesgo 0.314676 hormonas estrógeno 0.407972 Bowel Project 0.309666 Wickerham DL 0.323539 aromatasa anastrozol 0.350666 initial adjuvant therapy 0.311523 Breast Cancer Group 0.336508 Costantino JP 0.33801 P-2 Trial 0.309919 Bowel Project Study 0.309651 seno er 0.390638 developing invasive breast 0.321634 standard hormonal therapy 0.329685 adjuvant endocrine therapy 0.312843 Italian Tamoxifen Anastrozole 0.312927 breast cancer 0.858969 Breast Cancer Trialists 0.369705 IBIS-I breast 0.319452 Forbes JF 0.31136 enzima llamada 0.312883 tamoxifen treatment 0.320843 Cancer Institute 0.344896 seno her2 0.38128 primary breast 0.320324	CLICK HERE
15584	National Cancer Institute	Html	en	Childhood Cancer Genomics (PDQ®)–Health Professional Version	Expert-reviewed information summary about the genomics of childhood cancer. The summary describes the molecular subtypes for specific pediatric cancers and their associated clinical characteristics, the recurring genomic alterations that characterize each subtype at diagnosis or relapse, and the therapeutic and prognostic significance of the genomic alterations. The genomic alterations associated with brain tumors, kidney tumors, leukemias, lymphomas, sarcomas, and other cancers are discussed.	childhood cancers 0.451916 genomic landscape 0.448565 leukemia cell lines 0.468388 Leukemia Group study 0.460885 Pediatric Acute Myeloid 0.449186 B-cell precursor 0.478228 childhood B-cell precursor 0.465086 B-acute lymphoblastic leukemia 0.506359 poor prognosis 0.440387 mutations 0.5002 children 0.490055 acute lymphoblastic leukaemia 0.700198 specific mutations 0.439289 AML 0.440256 Childhood Acute Lymphoblastic 0.50969 acute lymphoblastic leukemias 0.496998 chromosomal abnormalities 0.446518 CEBPA mutations 0.439533 oncology group study 0.489092 leukemia development 0.4551 B-precursor Acute Lymphoblastic 0.495043 patients 0.462491 prognostic significance 0.476271 Nat Genet 0.458917 Hyperdiploid leukemia cells 0.465322	childhood cancer 0.441528 et al. 0.603959 lymphoblastic leukemia interacts 0.498545 high-risk acute 0.4447 pre-B cell leukemia 0.456422 Pediatr Blood Cancer 0.444419 acute myeloid leukemia 0.542492 Moorman AV 0.468863 acute lymphocytic leukemia 0.496126 acute lymphoblastic leukaemias 0.511116 favorable prognosis 0.439188 point mutations 0.44293 B-acute lymphoblastic leukaemia 0.466866 cases 0.445244 genomic alterations 0.438134 Abstract 0.573806 Clin Oncol 0.509945 favorable outcome 0.455497 blood 0.45817 Acute promyelocytic leukemia 0.495963 pathogenic germline mutations 0.450974 acute lymphoblastic leukemia 0.983229 acute leukemia 0.50127 Mullighan CG 0.471025	CLICK HERE
16834	National Cancer Institute	Html	en	Benefits of Nanotechnology for Cancer	Nanotechnology offers specific benefits that will enable the future of cancer care. Find out here what these benefits are.	red blood cells 0.289952 cancer treatment 0.2825 tumor endothelium barriers 0.421993 tumor blood vessels 0.384277 tumor interstitial fluid 0.381214 leaky vasculature 0.26567 drug delivery 0.676613 relatively large nanoparticles 0.291836 tumor region 0.406678 higher intratumoral accumulation 0.251171 traditional biological barriers 0.261085 nanoparticles 0.370499 negatively charged nanoparticles 0.284913 solid tumor treatment 0.521666 tumor site 0.484864 tumor stroma 0.468242 cancer drug delivery 0.312793 larger tumor mass 0.494058 acidic environment 0.280266 passive tumor accumulation 0.557879 e.g. biological barriers 0.246569 pancreatic cancer therapy 0.239135 tumor endothelium barrier 0.389992 large biological molecules 0.246874 cancer treatment efficacy 0.244109	tumor mass 0.83917 tumor tissue 0.353798 tumor stroma barrier 0.402359 fast growing tumor 0.412482 cancer cells 0.319257 acceptable drug delivery 0.271477 pancreatic cancer 0.267558 generation nanoparticle therapeutics 0.242211 nanoscale devices 0.277755 tumor cells 0.444134 e.g. functional barriers 0.237198 tumor masses 0.357375 Pancreatic cancer stroma 0.2599 interstitial fluid pressure 0.415697 water-insoluble nanoparticles 0.237625 biological barriers 0.281667 nanoparticle ‘passive tumor 0.434599 tumor penetration 0.354635 nanoparticle surface modification 0.243794 pancreatic cancer cell 0.255371 poorly functioning vasculature 0.239508 EPR effect 0.941886 efficient passive tumor 0.412347 tumor microenvironment 0.390631	CLICK HERE